NG101

Asset

Stage: Phase 2
Modality: Gene therapy
Target: Not known; 1
Indication: 0
Trials: 1
Developer

Indications

1

Wet age-related macular degeneration
Phase 2, hitnews.co.kr, 13 Oct 2026

In the full profile

Owner and partners1
Competitors1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.